Arkolith/Insider Trading/BTTX/Form 4

Karbe Frank

See Remarks, DirectorBetter Therapeutics, Inc. (BTTX) · full profile →Form 4 · filed Apr 12, 2023
Net Buying
Open-Market Buys
$201K
Open-Market Sells
$0
Net Open-Market Flow
$201K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 10, 2023Buy(P)242K$0.83$201K292K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-011189) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML